Healthcare / Medical DevicesShanghai
$42.21
+0.20 (+0.48%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-7.2M · quality 47.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
46/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.2B
P/E
48.0x
↑EV/EBITDA
24.4x
↑ROE
7.6%
↑Gross Margin
70.2%
↑Debt/Equity
0.02
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+4.6%
FCF CAGR
—
FCF margin
-2.9%
FCF / Net income
-0.12x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $431.6M · net income $102.6M · FCF $-12.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $431.6M | $431.6M | $424.5M | $340.8M | $376.9M |
| Net Income | $102.6M | $102.6M | $101.6M | $89.8M | $121.7M |
| EBITDA | $137.4M | $137.4M | $152.9M | $119.7M | $160.7M |
| EPS | 1.05 | 1.05 | 1.03 | 0.90 | 1.46 |
| Gross Margin | 70.2% | 70.2% | 72.0% | 71.1% | 68.6% |
| Operating Margin | 23.6% | 23.6% | 26.5% | 21.8% | 35.1% |
| Net Margin | 23.8% | 23.8% | 23.9% | 26.4% | 32.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 |
| Current Ratio | 4.89 | 4.89 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-12.7M | $-12.7M | $-7.2M | $61.8M | $72.4M |
| Returns | |||||
| ROE | 7.6% | 7.6% | 7.7% | 6.7% | 9.0% |
| Valuation | |||||
| P/E | 47.97 | 47.97 | 21.28 | 35.28 | 22.39 |
| EV/EBITDA | 24.36 | 24.36 | 11.22 | 18.26 | 9.70 |
| P/B | 3.07 | 3.07 | 1.65 | 2.35 | 2.02 |
| Growth & Yield | |||||
| Revenue Growth | 1.7% | 1.7% | 24.6% | -9.6% | — |
| EPS Growth | 1.8% | 1.8% | 14.8% | -38.5% | — |
| Dividend Yield | 2.9% | 2.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
52.8%
EPS terminal req.
$3.75
Spread vs growth
-51.1%
5Y implied EPS CAGR
34.0%
EPS terminal req.
$4.53
Spread vs growth
-32.2%
10Y implied EPS CAGR
21.4%
EPS terminal req.
$7.30
Spread vs growth
-19.6%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+45.0%
Start / end P/E
28.8x → 40.2x
EPS bridge
1.03 → 1.05
Residual
+0.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.